The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | A Phase I/II trial of glofitamab monotherapy in R/R MCL
Tycel Phillips, MD, City of Hope, Duarte, CA, discusses early results from a Phase I/II trial of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). The study found equal efficacy regardless of previous exposure to BTK inhibitors (BTKis), with durable responses, especially in those who achieved complete remission (CR). Common side effects included cytokine release syndrome (CRS), with minimal incidence of neurological complications observed. The long-term efficacy assessment was impacted by COVID-related incidents and deaths. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
